Pharmaceuticals company RPG Life Sciences announced Q4FY23 & FY23 results: Q4FY23: PBT up by 26% YoY for Q4FY23, maintaining the upward trajectory in EBITDA margins, which improved from 14.2% to 15.0% YoY Revenue from operations at Rs 118.49 crore registered a growth of 14% YoY for Q4FY23 FY23: For FY23, the company posted a jump in PBT by 25% YoY and recorded EBITDA margin expansion from 20.3% to 21.0% YoY Revenue from operations at Rs 512.81 crore registered a growth of 17% YoY for FY23 Yugal Sikri, Managing Director, RPG Life Sciences said, “In Q4 FY23, the company maintained its upward trajectory of overall robust performance by posting yet another strong result despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by a healthy 14% and 26% respectively YoY. EBITDA margins’ consistent upward trajectory has continued for the last 5 years, growing from 10.4% (FY19) to 15.9%(FY20) to 18.2% (FY21) to 20.3% (FY22) to 21.0% (FY23). The company continues to remain debt-free with the highest-ever net cashflow generated from operations in full-year FY23. Its domestic formulations business, the biggest contributor to the company’s business, recorded robust growth both in value and volume - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Our digitalization initiatives are showing strong traction. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has also shown robust growth, while emerging as another growth driver for the company, registering healthy growth in both sales and profits. The company is investing in plant upgradation and capacity expansion in both plants as well as working on building a healthy product pipeline to accelerate exports. Our relentless focus on achieving cost efficiencies in our operations, and eye on sales hygiene, are helping us to improve our margins consistently. We are well on course to implement our transformation agenda to achieve our strategic goals.” Result PDF
Pharmaceuticals firm RPG Life Sciences announced Q3FY23 results: Q3FY23 & 9MFY23: RPG Life Sciences posted a jump in PBT by 25% YoY for Q3FY23, maintaining the upward trajectory in EBITDA margins, which improved from 21.4% to 22.8% YoY. Revenue from operations at Rs 130.60 crores registered a growth of 13% YoY for Q3FY23. For 9MFY23 too, the company posted a jump in PBT by 25% YoY and recorded EBITDA margin expansion from 22.2% to 22.8% YoY. Revenue from operations at Rs 394.32 crores registered a growth of 17% YoY for 9MFY23. Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q3 FY23, Company maintained its upward trajectory of overall robust performance by posting yet another strong results despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by healthy 13% and 25% respectively YoY. EBITDA margin grew from 21.4% to 22.8% YoY. Domestic Formulations business, the biggest contributor to company business, recorded robust growth both in value and volumes - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Our digitalization initiatives are showing strong traction. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has also shown robust growth while API business has also picked up growth momentum. Our relentless focus on achieving cost efficiencies in our operations, eye on sales hygiene, is helping us to consistently improve our margins. We are well on course to implement our Transformation Agenda to achieve our strategic goals.” Result PDF
Conference Call with RPG Life Sciences Management and Analysts on Q2FY23 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company RPG Life Sciences announced Q2FY23 results: Q2FY23: RPG Life Sciences posted a jump in PBT by 21% YoY and by 8% QoQ EBITDA margins improved from 22.5% to 23.0% QoQ Revenue from operations at Rs 134.79 crores registered a growth of 20% YoY and a growth of 5% QoQ H1FY23: The company posted a jump in PBT by 25% YoY EBITDA margin expanded from 22.6% to 22.8% YoY Revenue from operations at Rs 263.72 crore registered a growth of 19% YoY Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q2FY23, the overall performance of the Company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by healthy 20% and 21% respectively YoY. EBITDA margin retained its upward trajectory growing from 22.5% to 23.0% QoQ. Domestic Formulations business has recorded a robust growth both in value and volumes - significantly and consistently ahead of market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has shown a robust growth while API business has also picked up growth momentum. Our relentless focus on achieving cost efficiencies in our operations and eye on sales hygiene is helping us to consistently improve our margins. We are on course to implement our Transformation Agenda to achieve our strategic goals.” Result PDF